Inspire Medical Systems stunned the market today. The stock jumped about 23% to US$64.14 after earnings, extending strong recent gains, even though Q2 revenue sat at US$200.6m and slipped against last year as coding and reimbursement issues weighed on implant volumes.

The real story sits on a longer clock. Inspire Medical Systems turned a small quarterly profit of roughly US$0.01 per share and delivered positive operating cash flow while revenue pressure remained, then paired that with a restructuring plan aimed at creating about US$30m of annual investment capacity. The next sections examine how that combination of pressure and profitability shapes the current balance of risk and reward.

Love the sharp move in Inspire Medical Systems after it returned to a small profit but uneasy about revenue pressure from coding and reimbursement issues? Check out the list of solid balance sheet and fundamentals stocks (49 results).

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$200.6m vs. US$217.1m (a decline of about 7.6%)
• Net Income, Q2 2026 vs. Q2 2025: US$0.3m vs. a loss of US$3.6m (shifted from a loss to a small profit)
• Basic EPS, Q2 2026 vs. Q2 2025: US$0.01 per share vs. a loss of US$0.12 per share (shifted from a loss to slight earnings)
• Adjusted EBITDA Margin, Q2 2026 vs. Q2 2025: 19.4% vs. 20.3% (a compression of about 0.9 percentage points)

Prefer clear visuals over scrolling through another wall of earnings tables and raw figures for Inspire Medical Systems? Get a full picture of the company with an easy to read view of its recent profitability trend and overall financials in the company report for Inspire Medical Systems.

Inspire Medical Systems: Profit And Cash Flow Support Bulls

Bulls argue that Inspire Medical Systems is a solid sleep apnea platform that can absorb temporary reimbursement noise and still grow into a larger neurostimulation niche. Q2 gives them some backing. Revenue fell 7.6% to US$200.6m, yet the company still produced US$0.01 of diluted EPS and a 19.4% adjusted EBITDA margin. Operating cash flow reached US$23.2m in the quarter and US$36.1m year to date, with US$415m of cash and investments and no debt. Management raised 2026 revenue guidance to a range of US$835m to US$875m and lifted adjusted EPS guidance to a range of US$1.05 to US$1.45. Project Horizon is expected to create about US$30m of annual investment capacity, which aligns with the bull view that the platform can self fund growth initiatives even while coding issues weigh on revenue.

Coding Headwinds And Execution Risks Keep Bear Case Alive

Bears focus on reimbursement disruption, execution missteps and heavy reliance on a single implant platform. Q2 does not close those files. Revenue declined 7.6%, and management attributes roughly US$40m of lost sales in the quarter and US$120m to US$130m for 2026 to coding, reimbursement and WISeR impacts. Guidance still points to an 8% to 10% year over year revenue decline for Q3 and only 4% to 6% adjusted operating margin for 2026, which fits the concern about pressured earnings visibility. Project Horizon carries US$20m to US$25m of pretax restructuring charges, mostly non cash, that will distort near term GAAP results. Ongoing legal expenses and an unusually high GAAP tax rate also support the view that Inspire Medical Systems has execution and policy work to do before revenue and margins stabilize.

Access the analyst estimates for Inspire Medical Systems to see where the consensus view on Inspire Medical Systems starts to break over the next few years and whether analyst models point to a quiet plateau or a sharper inflection in revenue and earnings.

Stay Ahead With Simply Wall St

If the swing in Inspire Medical Systems between coding headwinds and a return to a small profit has your attention, register for free with Simply Wall St and add it to your Watchlist to watch how the share price lines up against fair value and wait for an entry point that fits your plan. Once you are invested, use the Portfolio Command Center to cut through noise and focus on the most important updates to your holdings. For longer term perspective, lean on the Community to see how other investors are thinking about key risks and potential catalysts. With that full view, you can spot important changes early and stay a step ahead of the market.

Seeking Alternatives Beyond Inspire Medical Systems?

Fresh ideas do not stay under the radar for long. Some stocks build quiet momentum, others are already breaking out. Check these focused lists before the crowd catches up and act now.

• Scan for cash rich compounders with steady momentum by reviewing the curated list of solid balance sheet and fundamentals stocks (49 results) that can help anchor your portfolio when single stock stories get bumpy.
• Ride the next leg of the AI build out by checking companies powering the chips, servers and data centers inside 55 AI infrastructure stocks while that edge is still underused.
• Target future growth themes at the intersection of medicine and algorithms by tracking companies in 41 healthcare AI stocks before this corner of the market goes from quiet to crowded.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.